Plain-English translation of NCT07197580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new radioactive medication called 177Lu-TLX250 (lutetium girentuximab tetraxetan) in people with advanced clear cell renal cell carcinoma—a type of kidney cancer that has come back or spread despite previous treatments. The medication is designed to target cancer cells that express a specific protein called CAIX. Researchers will compare this new treatment to other standard single-agent therapies that your doctor would normally choose.
People with advanced kidney cancer that has recurred or progressed despite at least two prior treatment lines often have limited options and poor outcomes. This medication represents a new approach using radioactive molecules to directly target cancer cells, and researchers want to see if it can help patients live longer and have fewer side effects than currently available options.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two dosing schedules of the radioactive medication through intravenous infusions. Some participants will receive 3 infusions spaced 8 weeks apart, while others will receive 6 infusions spaced 4 weeks apart. You will visit the clinic for each infusion, have regular blood tests and imaging scans to monitor how your cancer responds, and report any side effects to your care team.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Australia